Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy

Amanda Shanks Huynh, Woo Jin Chung, Hyun Il Cho, Valerie E. Moberg, Esteban Celis, David L. Morse, Josef Vagner

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Toll-like receptor 2 (TLR2) is a target for immune system stimulation during cancer immunotherapy and a cell-surface marker for pancreatic cancer. To develop targeted agents for cancer imaging and therapy, we designed, synthesized, and characterized 13 novel, fully synthetic high affinity TLR2 agonists. Analogue 10 had the highest agonist activity (NF-κB functional assay, EC50 = 20 nM) and binding affinity (competitive binding assay, Ki = 25 nM). As an immune adjuvant, compound 10 stimulated the immune system in vivo by generation and persistence of antigen-specific CD8+ T cells indicating its potential use in cancer immunotherapy. After conjugation of near-infrared dye to 10, agonist activity (EC50 = 34 nM) and binding affinity (Ki = 11 nM) were retained in 13. Fluorescence signal was present in TLR2 expressing pancreatic tumor xenografts 24 h after injection of 13, while an excess of unlabeled ligand blocked 13 from binding to the tumor, resulting in significantly decreased signal (p < 0.001) demonstrating in vivo selectivity.

Original languageEnglish (US)
Pages (from-to)9751-9762
Number of pages12
JournalJournal of Medicinal Chemistry
Volume55
Issue number22
DOIs
StatePublished - Nov 26 2012

Fingerprint

Toll-Like Receptor 2
Pancreatic Neoplasms
Immunotherapy
Ligands
Neoplasms
Immune System
CD8 Antigens
Competitive Binding
Heterografts
Coloring Agents
Fluorescence
T-Lymphocytes
Injections

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Huynh, A. S., Chung, W. J., Cho, H. I., Moberg, V. E., Celis, E., Morse, D. L., & Vagner, J. (2012). Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy. Journal of Medicinal Chemistry, 55(22), 9751-9762. https://doi.org/10.1021/jm301002f

Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy. / Huynh, Amanda Shanks; Chung, Woo Jin; Cho, Hyun Il; Moberg, Valerie E.; Celis, Esteban; Morse, David L.; Vagner, Josef.

In: Journal of Medicinal Chemistry, Vol. 55, No. 22, 26.11.2012, p. 9751-9762.

Research output: Contribution to journalArticle

Huynh, Amanda Shanks ; Chung, Woo Jin ; Cho, Hyun Il ; Moberg, Valerie E. ; Celis, Esteban ; Morse, David L. ; Vagner, Josef. / Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy. In: Journal of Medicinal Chemistry. 2012 ; Vol. 55, No. 22. pp. 9751-9762.
@article{f8ec209ec75743729a933676a7eeb6a1,
title = "Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy",
abstract = "Toll-like receptor 2 (TLR2) is a target for immune system stimulation during cancer immunotherapy and a cell-surface marker for pancreatic cancer. To develop targeted agents for cancer imaging and therapy, we designed, synthesized, and characterized 13 novel, fully synthetic high affinity TLR2 agonists. Analogue 10 had the highest agonist activity (NF-κB functional assay, EC50 = 20 nM) and binding affinity (competitive binding assay, Ki = 25 nM). As an immune adjuvant, compound 10 stimulated the immune system in vivo by generation and persistence of antigen-specific CD8+ T cells indicating its potential use in cancer immunotherapy. After conjugation of near-infrared dye to 10, agonist activity (EC50 = 34 nM) and binding affinity (Ki = 11 nM) were retained in 13. Fluorescence signal was present in TLR2 expressing pancreatic tumor xenografts 24 h after injection of 13, while an excess of unlabeled ligand blocked 13 from binding to the tumor, resulting in significantly decreased signal (p < 0.001) demonstrating in vivo selectivity.",
author = "Huynh, {Amanda Shanks} and Chung, {Woo Jin} and Cho, {Hyun Il} and Moberg, {Valerie E.} and Esteban Celis and Morse, {David L.} and Josef Vagner",
year = "2012",
month = "11",
day = "26",
doi = "10.1021/jm301002f",
language = "English (US)",
volume = "55",
pages = "9751--9762",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "22",

}

TY - JOUR

T1 - Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy

AU - Huynh, Amanda Shanks

AU - Chung, Woo Jin

AU - Cho, Hyun Il

AU - Moberg, Valerie E.

AU - Celis, Esteban

AU - Morse, David L.

AU - Vagner, Josef

PY - 2012/11/26

Y1 - 2012/11/26

N2 - Toll-like receptor 2 (TLR2) is a target for immune system stimulation during cancer immunotherapy and a cell-surface marker for pancreatic cancer. To develop targeted agents for cancer imaging and therapy, we designed, synthesized, and characterized 13 novel, fully synthetic high affinity TLR2 agonists. Analogue 10 had the highest agonist activity (NF-κB functional assay, EC50 = 20 nM) and binding affinity (competitive binding assay, Ki = 25 nM). As an immune adjuvant, compound 10 stimulated the immune system in vivo by generation and persistence of antigen-specific CD8+ T cells indicating its potential use in cancer immunotherapy. After conjugation of near-infrared dye to 10, agonist activity (EC50 = 34 nM) and binding affinity (Ki = 11 nM) were retained in 13. Fluorescence signal was present in TLR2 expressing pancreatic tumor xenografts 24 h after injection of 13, while an excess of unlabeled ligand blocked 13 from binding to the tumor, resulting in significantly decreased signal (p < 0.001) demonstrating in vivo selectivity.

AB - Toll-like receptor 2 (TLR2) is a target for immune system stimulation during cancer immunotherapy and a cell-surface marker for pancreatic cancer. To develop targeted agents for cancer imaging and therapy, we designed, synthesized, and characterized 13 novel, fully synthetic high affinity TLR2 agonists. Analogue 10 had the highest agonist activity (NF-κB functional assay, EC50 = 20 nM) and binding affinity (competitive binding assay, Ki = 25 nM). As an immune adjuvant, compound 10 stimulated the immune system in vivo by generation and persistence of antigen-specific CD8+ T cells indicating its potential use in cancer immunotherapy. After conjugation of near-infrared dye to 10, agonist activity (EC50 = 34 nM) and binding affinity (Ki = 11 nM) were retained in 13. Fluorescence signal was present in TLR2 expressing pancreatic tumor xenografts 24 h after injection of 13, while an excess of unlabeled ligand blocked 13 from binding to the tumor, resulting in significantly decreased signal (p < 0.001) demonstrating in vivo selectivity.

UR - http://www.scopus.com/inward/record.url?scp=84869989377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869989377&partnerID=8YFLogxK

U2 - 10.1021/jm301002f

DO - 10.1021/jm301002f

M3 - Article

C2 - 23098072

AN - SCOPUS:84869989377

VL - 55

SP - 9751

EP - 9762

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 22

ER -